Skip to content
Screener

Savara SVRA Free cash flow margin

Discontinued — last reported Q4 '20

Free cash flow margin at other companies

Innoviva, Inc. logo
Innoviva, Inc.INVA
43.1%-11.1pp
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-75%-30.5pp
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
17.7%+0.9pp
PVL
Palvella TherapeuticsPVLA
-99.8%-34.2pp
United Therapeutics logo
United TherapeuticsUTHR
34.6%-0.1pp
Insmed logo
InsmedINSM
-71%-28.6pp

Other financials

Income statement

See full
Revenue-—
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$38.8M+98.4%
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.19B+156%
Enterprise value$1.19B+148%

Profitability

See full
Operating margin-19,183.3%—
Net margin-19,305.1%—

Returns & leverage

See full
Return on equity-80%+4.7pp
Debt / equity0.2×0.0×
Current ratio13.5×-1.4×

Where this comes from

Calculated from Savara’s reported figures.

free cash flow/total revenue=-15,518.7%

Based on trailing twelve months.

The source filing: Savara’s 10-K, filed March 30, 2022. Open the filing →

Filed
Mar 30, 2022, 4:08 PM EDT
Fiscal year
FY2021
Accession
0000950170-22-005045

FAQ

What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.